Compare Logitech International SA (LOGI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Summit Therapeutics Inc — how do they compare? Logitech International SA trades at $104.42 (market cap $14.65B), while Summit Therapeutics Inc trades at $14.4 (market cap $10.48B). The key difference: Logitech International SA is the larger of the two by market cap, and Logitech International SA pays a 1.67% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| LOGI | SMMT | |
|---|---|---|
Market Cap | $14.65B | $10.48B |
Sector | Technology | Health |
52-Week High | $126.69 | $29.32 |
52-Week Low | $85.84 | $13.05 |
Enterprise Value | $13.00B | $9.90B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $101.83, down 0.98% on the day, with a bullish technical outlook supported by moving averages and strong fundamentals including a 14.69% net margin and consistent earnings beats. Recent product launches like the G3 Series and Spotlight 2 presenter highlight innovation, while a partnership with Call of Duty: Modern Warfare 4 boosts gaming segment prospects. Cash flow trends show operational strength with 2025 operating cash flow at $842.56M.
The stock offers upside to the $113 consensus price target, driven by B2B and AI product expansion, but faces risks from competitive pressures and reliance on consumer spending. Analyst sentiment is mixed with 26% buy ratings, suggesting cautious optimism amid valuation metrics like a P/E of 21.43.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
